RNA Technologies in Cardiovascular Medicine and Research
Editat de Volker A. Erdmann, Wolfgang Poller, Jan Barciszewskien Limba Engleză Hardback – 8 iul 2008
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1570.65 lei 6-8 săpt. | |
Springer Berlin, Heidelberg – 18 oct 2010 | 1570.65 lei 6-8 săpt. | |
Hardback (1) | 1576.03 lei 6-8 săpt. | |
Springer Berlin, Heidelberg – 8 iul 2008 | 1576.03 lei 6-8 săpt. |
Preț: 1576.03 lei
Preț vechi: 1658.98 lei
-5% Nou
Puncte Express: 2364
Preț estimativ în valută:
301.59€ • 317.29$ • 249.70£
301.59€ • 317.29$ • 249.70£
Carte tipărită la comandă
Livrare economică 14-28 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783540787082
ISBN-10: 3540787089
Pagini: 376
Ilustrații: XIV, 358 p. 55 illus.
Dimensiuni: 155 x 235 x 30 mm
Greutate: 0.66 kg
Ediția:2008
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3540787089
Pagini: 376
Ilustrații: XIV, 358 p. 55 illus.
Dimensiuni: 155 x 235 x 30 mm
Greutate: 0.66 kg
Ediția:2008
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany
Public țintă
ResearchDescriere
In this book the authors review the field and explore the potential role of RNAi and other RNA technologies in cardiovascular medicine and research. They highlight the impressive recent progress but also the hurdles that still must be overcome before this promising technology is finally ready for translation and clinical use.
Cuprins
Preface.- Part I - MicroRNA.- An overview of microRNA. MicroRNAs and their potential. miRNAs and their emerging role in cardiac hypertrophy. MicroRNAs and the control of heart pathophysiology. MicroRNA systems biology.- Part II - RNA interference.- Targeting viral heart disease by RNA interference. Design of siRNAs and shRNAs for RNA interference: possible clinical applications. RNA interference and microRNA modulation for the treatment of cardiac disorders. Cardiac delivery of nucleic acids by transcriptional and transductional targeting of adeno-associated viral vectors.- Part III - Ribozymes.- Characterization of hammerhead ribozymes potentialy suitable for the treatment of hyperproliferative vascular diseases. Applications of ribozymes and pyrrole-imidazole polyamides for cardiovascular and renal diseases.- Part IV. - Noncoding, aptamer and antisense RNAs.- Noncoding RNAs in human diseases. Aptamers and siRNAs in cardiovascular disease. Nucleic Acid Aptamers for Cardiovascular Therapeutics. NFkB decoy oligodeoxynucleotide-based therapy in cardiovascular diseases. Antisense therapy for restenosis following percutaneous coronary intervention.Toxic RNA in pathogenesis of human neuromuscular disorders.
Textul de pe ultima copertă
Cardiovascular disease is the number one cause of death worldwide. In 2005 17.5 million people, representing 30% of all global deaths, died of cardiovascular disease. For this reason every effort needs to be made to improve the early diagnosis and treatment procedures for combating this disease. This book - edited by Professors Erdmann and Barciszewski, both internationally recognised experts in the field of RNA molecular biology, and Professor Poller, an internationally respected expert in cardiology - will offer more than an introduction to these fields. More importantly, it will also lead the reader to the newest developments in RNA methods and technologies and show how they are currently employed for the diagnosis and treatment of cardiovascular disease. This book is also a must for all those interested in knowing more about the molecular medicine of tomorrow and how it will be revolutionised by its newest approach - RNA technologies.
Caracteristici
Currently no comprehensive overview on potential and challenges of RNAi and other RNA technologies for basic cardiovascular biology and for the clinical management of patients with cardiovascular disorders
Book will be comprehensive in that it does not only treat the phenomenon of RNAi in all its facets (as most recently published books), but does explicitly cover the many other aspects of the “RNA World” (pathogenic and therapeutic potential of microRNAs, aptamer technology, etc.), too
With this significantly broadened scope as compared to currently existing books it appears to be an urgently needed new publication
Includes supplementary material: sn.pub/extras
Book will be comprehensive in that it does not only treat the phenomenon of RNAi in all its facets (as most recently published books), but does explicitly cover the many other aspects of the “RNA World” (pathogenic and therapeutic potential of microRNAs, aptamer technology, etc.), too
With this significantly broadened scope as compared to currently existing books it appears to be an urgently needed new publication
Includes supplementary material: sn.pub/extras